MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Transcode Therapeutics, Inc. (RNAZ)

Transcode Therapeutics, Inc. (RNAZ)

|||

Balance Sheets Overview

Current Ratio
197.14%
Quick Ratio
197.14%
Cash Ratio
155.28%
Debt to Asset Ratio
8.38%
Unit: Dollar
Assets Breakdown
    • Intangible assets
    • Goodwill
    • Cash
    • Due from related party
Liabilities Breakdown
    • Series a non-voting convertible ...
    • Accumulated deficit
    • Additional paid-in capital
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash
8,383,393
12,835,454
17,813,521
2,835,916
Grant receivable
-
-
952,460
198,296
Reimbursement right
-
2,297,806
2,297,806
-
Due from related party
638
638
638
-
Prepaid expenses and other current assets
2,259,120
1,615,096
919,440
1,716,836
Total current assets
10,643,151
16,748,994
21,983,865
4,751,048
Property and equipment, net of depreciation
322,809
346,745
370,681
19,908
Goodwill
25,744,143
25,744,143
25,744,143
-
Intangible assets
114,300,000
114,300,000
114,300,000
-
Deferred offering costs
-
25,000
-
455,726
Total assets
151,010,103
157,164,882
162,398,689
5,226,682
Accounts payable and accrued expenses
4,682,359
5,293,308
3,494,220
2,967,828
Notes payable - convertible, at fair value
652,411
-
-
-
Total current liabilities
5,398,717
5,378,570
3,494,220
2,967,828
Warrant liability
330,526
559,747
434,399
832,875
Contingent consideration
6,465,000
6,248,000
6,364,000
-
Deferred tax liability
457,677
457,377
226,068
-
Long-term liabilities
7,253,203
7,265,124
7,024,467
832,875
Total liabilities
12,651,920
12,643,694
10,518,687
3,800,703
Series a non-voting convertible preferred stock - 0.0001 par value per share 1,242.0718 shares authorized at june 30, 2026, and december 31, 2025 1,212.1822 shares issued and outstanding at june 30, 2026, and december 31, 2025-Series APreferred Stock
143,384,776
143,269,761
141,544,536
-
Series a non-voting convertible preferred stock - 0.0001 par value per share 1,242.0718 shares authorized at june 30, 2026, and december 31, 2025 1,212.1822 shares issued and outstanding at june 30, 2026, and december 31, 2025-Series BPreferred Stock
22,668,324
-
-
-
Non-voting convertible preferred stock
121
121
-
-
Common stock - 0.0001 par value per share 290,000,000 shares authorized at june 30, 2026, and december 31, 2025 1,011,595 and 916,968 shares issued and outstanding at june 30, 2026, and december 31, 2025, respectively
101
92
92
84
Additional paid-in capital
94,703,052
116,899,277
108,198,366
85,845,777
Accumulated deficit
-122,398,191
-115,648,063
-97,862,992
-84,419,882
Total stockholders' equity (deficit)
-27,694,917
1,251,427
10,335,466
1,425,979
Total liabilities, series a non-voting convertible preferred stock, series b non-voting convertible preferred stock, and stockholders' equity (deficit)
151,010,103
157,164,882
162,398,689
5,226,682
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash$8,383,393 (13.68%↑ Y/Y)Prepaid expenses andother current assets$2,259,120 (227.04%↑ Y/Y)Due from relatedparty$638 Intangible assets$114,300,000 Goodwill$25,744,143 Total current assets$10,643,151 (29.14%↑ Y/Y)Property and equipment,net of depreciation$322,809 (1207.50%↑ Y/Y)Total assets$151,010,103 (1726.79%↑ Y/Y)Accumulated deficit-$122,398,191 (-53.84%↓ Y/Y)Total liabilities,series a non-voting...$151,010,103 (1726.79%↑ Y/Y)Total stockholders'equity (deficit)-$27,694,917 (-550.49%↓ Y/Y)Additional paid-in capital$94,703,052 (10.49%↑ Y/Y)Non-voting convertiblepreferred stock$121 Common stock - 0.0001par value per share...$101 (20.24%↑ Y/Y)Series a non-votingconvertible preferred stock...$143,384,776 Series a non-votingconvertible preferred stock...$22,668,324 Total liabilities$12,651,920 (497.15%↑ Y/Y)Long-term liabilities$7,253,203 (1209.92%↑ Y/Y)Total currentliabilities$5,398,717 (244.97%↑ Y/Y)Contingent consideration$6,465,000 Deferred tax liability$457,677 Warrant liability$330,526 (-40.31%↓ Y/Y)Accounts payable andaccrued expenses$4,682,359 (199.19%↑ Y/Y)Notes payable -convertible, at fair value$652,411